

- F1 Impact of Food Allergy On Work Productivity And Healthcare Resource Use In Patients With Allergic Asthma Treated With Omalizumab  
Funded by Genentech, Inc
- F2 Real-world Outcomes with Mepolizumab in Patients with Severe Eosinophilic Asthma According to Smoking History and COPD status at Enrollment: Realiti-A post hoc analysis  
Funded by GSK
- F3 Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Atopic Dermatitis in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age  
Funded by Dermavant
- F4 The impact of mepolizumab on fatigue and work impairment in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): Analysis from SYNAPSE study  
Funded by GSK
- F5 Clinical remission (CR) in patients with severe eosinophilic asthma (SEA): an analysis of SIROCCO and CALIMA trial data  
Funded by AstraZeneca
- F6 Rocatinlimab Demonstrates Improvements in Patient-Reported Outcomes in Adult Patients with Moderate-to-Severe Atopic Dermatitis in a Phase 2B Trial  
Funded by Kyowa Kirin Co., Ltd
- F7 Rocatinlimab Demonstrates a Significant Reduction in IgE Concentrations in Addition to Clinical Efficacy Measures in Patients with Moderate-to-Severe Atopic Dermatitis in a Randomized, Double-Blind, Placebo-Controlled Phase 2B Trial  
Funded by Kyowa Kirin Co., Ltd
- F8 US patients with chronic rhinosinusitis with nasal polyps enrolled in the AROMA registry have a high burden of disease at baseline regardless of clinician specialty  
Funded by Regeneron and Sanofi
- F9 Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) had fewer sinus procedures and less healthcare resource utilization (HCRU) after initiating dupilumab in real-world practice  
Funded by Sanofi and Regeneron Pharmaceuticals Inc
- F10 Improved Lung Function is Associated with Better Asthma Control in Adolescents and Adults Aged 12 Years and Older with Moderate-to-Severe Type 2 Asthma: A Post hoc Analysis of QUEST  
Funded by Sanofi and Regeneron Pharmaceuticals Inc
- F11 Dupilumab Treatment Shows Consistent Improvement in Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 17 Years: Results From an Open-Label Extension Study  
Funded by Sanofi and Regeneron Pharmaceuticals Inc
- F12 Children With Atopic Dermatitis Respond More Rapidly to Dupilumab Treatment in Comparison to Adolescents and Adults  
Funded by Sanofi and Regeneron Pharmaceuticals Inc
- F13 Understanding the Impact of Long-Term Prophylaxis Switches for Patients With Hereditary Angioedema  
Funded by Takeda Pharmaceuticals USA, Inc.
- F14 Lanadelumab Effectiveness and Safety in Adolescent Patients With Hereditary Angioedema Aged 12 to <18 Years: Pooled Results From the Real-World ENABLE and EMPOWER Studies  
Funded by Takeda Pharmaceuticals USA, Inc.
- F15 Effect of tezepelumab in patients with severe, uncontrolled asthma by age of onset, allergic status, and eosinophilic phenotype  
Funded by AstraZeneca and Amgen Inc..
- F16 Tezepelumab efficacy in dupilumab-eligible patients: a pooled analysis from the PATHWAY and NAVIGATOR studies  
Funded by AstraZeneca and Amgen, Inc.
- F17 Clinical responses to tezepelumab in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps from the NAVIGATOR study  
Funded by AstraZeneca and Amgen, Inc.
- F18 Effect of Dupilumab Treatment on Mucus Plugging and Mucus Volume in Type 2 Asthma: The Phase 4 VESTIGE Trial  
Funded by Sanofi and Regeneron Pharmaceuticals Inc.
- F19 Dupilumab Reduces Disease Activity in Patients with Chronic Spontaneous Urticaria: LIBERTY-CSU CUPID Study A  
Funded by Sanofi and Regeneron Pharmaceuticals Inc.
- F20 Long-term safety and efficacy with garadacimab for hereditary angioedema prophylaxis in an open-label extension study  
Funded by CSL Behring
- F21 Long-term efficacy and safety of subcutaneous garadacimab for prophylaxis of hereditary angioedema attacks: Results from the open-label extension of a multicentre phase 3 study  
Funded by CSL Behring

- F22 Early onset of protection against hereditary angioedema attacks from Week 1 with garadacimab in pivotal Phase 3 (VANGUARD) study  
Funded by CSL Behring
- F23 Trends in volume of on-demand hereditary angioedema treatments in the US: A retrospective analysis of a large multi-payer claims database  
Funded by KalVista Pharmaceuticals
- F24 Healthcare costs among commercially-insured patients with hereditary angioedema managed with long-term prophylaxis: A retrospective US claims database analysis  
Funded by KalVista Pharmaceuticals
- F25 neffy, epinephrine nasal spray, Demonstrates a Positive Efficacy and Safety Profile for the Treatment of Allergic Reactions in Pediatric Patients at-Risk of Anaphylaxis: Phase 3 Study Results  
Funded by ARS Pharma
- F26 Insights Into APDS: Revealing the Patient Experience  
Funded by Pharming Healthcare, Inc.
- F27 Initial Results from Summit: An On-going, 3-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)  
Funded by Cogent Biosciences, Inc.
- F28 Burden of the Untreated Attacks and its Impact on Social, Mental and Physical Health  
Funded by KalVista Pharmaceuticals.
- F29 Amlitelimab Improves Extent and Severity of Disease in Adults with Moderate-to-Severe Atopic Dermatitis (AD): 24-Week Results from a Phase 2b Trial (STREAM-AD)  
Funded by Sanofi
- F30 Improvements on Patient-Reported Outcome (PRO) Measures With 24 Weeks of Amlitelimab Treatment in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Trial (STREAM-AD)  
Funded by Sanofi
- F31 Pharmacokinetics and Pharmacodynamics of Epinephrine Following Administration via Sublingual Film, Autoinjector, or Manual Injection  
Funded by Aquestive Therapeutics
- F32 Epinephrine Administered via Sublingual Film, Manual Injection, or Auto-Injectors in Healthy Adults: Pharmacodynamic Results  
Funded by Aquestive Therapeutics
- F33 Predicting Abrocitinib Efficacy at Week 12 in Patients With Moderate-to-Severe Atopic Dermatitis Based on Their Week 4 Response: A Post Hoc Analysis of 4 Randomized Studies  
Funded by Pfizer, Inc.
- F34 Effect of Abrocitinib and Dupilumab on Eosinophil Levels in Patients With Moderate-to-Severe Atopic Dermatitis and With or Without Comorbid Asthma or Allergic Rhinitis: A Post Hoc Pooled Analysis of JADE COMPARE and JADE DARE  
Funded by Pfizer, Inc.
- F35 Efficacy of albuterol-budesonide asthma rescue inhaler in adults with moderate-to-severe asthma with exercise as a trigger: post-hoc sub-group analysis of MANDALA  
Funded by: AstraZeneca
- F36 The Use of Beta-Alanine for the Management of Aquagenic Pruritus  
Degala and Degala
- F37 Ferret-Monosensitization: An Unusual Allergen in Pediatric Rhinosinusitis  
Satnarine, Kleiner, and Gans
- F38 A Single Center Case Series Study of Immune Dysregulation Presenting as Treatment-Refractory Autoimmune Cytopenia in Kabuki Syndrome  
Nomula et al
- F39 Severe Atopic Dermatitis and Asthma Pediatric Patient Shows Marked Improvement on Tralokinumab While Refractory on First Line Therapy  
Navasero et al
- F40 Shared Decision-Making as a Resource for Assessing Disease Burden and Management of Chronic Spontaneous Urticaria  
Gutierrez et al
- F41 An Atypical Hypersensitivity Reaction to Acetaminophen  
Harrison and Rozario